Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Rubin

Showing results (81-90 of 125) with videos related to

Pageof 13
Sort By:
CNS Drugs|October 7, 2024
An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity DisorderAnn Childress, Andrew J Cutler, Lenard A Adler, et al.
The Journal of Biological Chemistry|August 31, 2013
Ion-specific effects on prion nucleation and strain formationJonathan Rubin, Hasan Khosravi, Kathryn L Bruce, et al.
Psychiatry Research|January 8, 2021
Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trialsStephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Plos Biology|July 27, 2018
Auditory midbrain coding of statistical learning that results from discontinuous sensory stimulationHugo Cruces-Solís, Zhizi Jing, Olga Babaev, et al.
Neuropsychiatric Disease and Treatment|June 11, 2021
The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled TrialsAzmi Nasser, Joseph T Hull, Tesfaye Liranso, et al.
Current Geriatrics Reports|September 27, 2016
Relationship Between Accelerometer-Measured Activity and Self-Reported or Performance-Based Function in Older Adults with Severe Aortic StenosisYufei Tang, Philip Green, Mathew Maurer, et al.
British Journal of Clinical Pharmacology|May 19, 2022
The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorderAzmi Nasser, Roberto Gomeni, Zhao Wang, et al.
Atherosclerosis|October 4, 2012
Hyperglycemia and arterial stiffness: the Atherosclerosis Risk in the Communities studyJonathan Rubin, Vijay Nambi, Lloyd E Chambless, et al.
The Journal of Molecular Diagnostics : JMD|July 27, 2024
A Network-Based Framework to Discover Treatment-Response-Predicting Biomarkers for Complex DiseasesUday S Shanthamallu, Casey Kilpatrick, Alex Jones, et al.
Psychiatry Research|November 14, 2022
Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trialStephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Pageof 13

Showing results (81-90 of 125) with videos related to

Sort By:
Pageof 13
CNS Drugs|October 7, 2024
An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity DisorderAnn Childress, Andrew J Cutler, Lenard A Adler, et al.
The Journal of Biological Chemistry|August 31, 2013
Ion-specific effects on prion nucleation and strain formationJonathan Rubin, Hasan Khosravi, Kathryn L Bruce, et al.
Psychiatry Research|January 8, 2021
Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trialsStephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Plos Biology|July 27, 2018
Auditory midbrain coding of statistical learning that results from discontinuous sensory stimulationHugo Cruces-Solís, Zhizi Jing, Olga Babaev, et al.
Neuropsychiatric Disease and Treatment|June 11, 2021
The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled TrialsAzmi Nasser, Joseph T Hull, Tesfaye Liranso, et al.
Current Geriatrics Reports|September 27, 2016
Relationship Between Accelerometer-Measured Activity and Self-Reported or Performance-Based Function in Older Adults with Severe Aortic StenosisYufei Tang, Philip Green, Mathew Maurer, et al.
British Journal of Clinical Pharmacology|May 19, 2022
The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorderAzmi Nasser, Roberto Gomeni, Zhao Wang, et al.
Atherosclerosis|October 4, 2012
Hyperglycemia and arterial stiffness: the Atherosclerosis Risk in the Communities studyJonathan Rubin, Vijay Nambi, Lloyd E Chambless, et al.
The Journal of Molecular Diagnostics : JMD|July 27, 2024
A Network-Based Framework to Discover Treatment-Response-Predicting Biomarkers for Complex DiseasesUday S Shanthamallu, Casey Kilpatrick, Alex Jones, et al.
Psychiatry Research|November 14, 2022
Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trialStephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
Pageof 13